ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025
Distal median nerve dysfunction and carpal tunnel syndrome in people with multiple sclerosis treated with teriflunomide: an electrodiagnostic study.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTrials demonstrated an increased risk of distal median nerve dysfunction (DMND) and carpal tunnel syndrome (CTS) associated with teriflunomide in people with multiple (pwMS).
objectiveTo estimate the real-world prevalence of clinical CTS and electrodiagnostic DMND in teriflunomide-treated pwMS.
methodsCross-sectional study on selected teriflunomide (WHOATC code: L04AK02)-treated, risk factor-free pwMS at the Isfahan MS clinic in 2022. CTS was diagnosed through history and physical examination, and DMND was diagnosed by nerve conduction studies (NCS). Outcome consisted of an ordinal scale of DMND as follows: no DMND, all values within normal limits; mild, sensory conduction velocity < 40 m/s with motor onset latency < 4.5ms; moderate, motor onset latency between 4.5-6.5ms; severe, motor onset latency > 6.5ms with amplitude > 0.2mV; and very severe, motor amplitude < 0.2mV.
results52 participants were included (median [range] duration of teriflunomide treatment: 3 [18] years); 5.8% were diagnosed with CTS, yet, 51.9% showed at least some evidence of DMND; of the 104 hands, 25% showed mild, 11.5% moderate, 2.9% severe, and none showed very severe DMND. Right hand side (aβ [SE]: 0.67 [0.26]; p = 0.01), duration of MS (aβ [SE]: -0.14 [0.05]; p = 0.01) and age (aβ [SE]: 0.06 [0.03]; p = 0.05) were associated with a worse grade of DMND, while the association of DMND grade with sex, EDSS score, duration of teriflunomide treatment, and prior DMT, were not confirmed (all p values > 0.05).
conclusionA considerable proportion of teriflunomide-treated pwMS had DMND in at least one hand. The etiology, along its optimal management strategy, remains to be explored.
Indexed as
Identifiers
39613939What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.